Sanofi to Highlight New Data from the P-II Study of Frexalimab for the Treatment of Multiple Sclerosis at AAN 2024
Shots:
- The P-II trial assesses the safety, efficacy, tolerability & PK profile of frexalimab (high dose: 1200mg, IV, Q4W with 1800mg loading dose & low dose: 300mg, SC, Q2W with 600mg loading dose) vs PBO to treat relapsing MS for 12wks. after which PBO patients will switch to frexalimab arms
- The results showed, 96% (high dose) & 87% (low dose) of patients were Gd+ T1 lesion-free at wk.48 while those who switched had declines at wk.24 with 90% (high dose) & 92% (low dose) lesion-free at wk.48
- At wk.48, new/growing Gd+ T2 lesions remained low with stable lymphocyte counts. ARR of 0.04 was seen at high dose with 96% free of relapses & 0.22 was seen at an initial low dose with 0.09 (high dose) & 0.40 (low dose) in those who switched
Ref: Globenewswire | Image: Sanofi
Related News:- Sanofi Reports Results for Frexalimab in P-II Trial for the Treatment of Relapsing Multiple Sclerosis (MS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
